title: Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
authors.forename: Matthijs
authors.initials: M
authors.lastname: van Luin
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Brouwer
authors.forename: Andre
authors.initials: A
authors.lastname: van der Ven
authors.forename: Wiel
authors.initials: W
authors.lastname: de Lange
authors.forename: Ron H N
authors.initials: RH
authors.lastname: van Schaik
authors.forename: David M
authors.initials: DM
authors.lastname: Burger
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D048588:Benzoxazines / Q000009:adverse effects*; D003521:Cyclopropanes; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D048588:Benzoxazines; D003521:Cyclopropanes; C098320:efavirenz; D012293:Rifampin